Genetic and epidemiological studies have found that variations in the amyloid precursor protein (APP) and the apoliopoprotein E (APOE) genes represent major modifiers of the progressive neurodegeneration in Alzheimer's disease (AD). An extra copy or gain-of-function mutations in APP lower age of AD onset. Compared to the other isoforms (APOE3 and APOE2), the ε4 allele of APOE (APOE4) hastens and exacerbates early and late onset forms of AD. Convenient in vivo models to study how APP and APOE4 interact at the cellular and molecular level to influence neurodegeneration are lacking. Here, we show that the nematode C. elegans can model important aspects of AD including age-related, patterned neurodegeneration that is exacerbated by APOE4. Specifically, we found that APOE4, but not APOE3, acts with APP to hasten and expand the pattern of cholinergic neurodegeneration caused by APP. Molecular mechanisms underlying how APP and APOE4 synergize to kill some neurons while leaving others unaffected may be uncovered using this convenient worm model of neurodegeneration. Short running title: In vivo neurodegeneration with APP and APOE4
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease which cannot be prevented, cured, or decelerated. About 11% of people older than 65 in the US currently suffer from AD (Alzheimer's Association 2015) . Genetic and epidemiological studies have linked variation in several genes strongly to AD. Gain-of-function mutations in amyloid precursor protein (APP) or in presenilin genes associated with processing APP are linked to early-onset AD (Goate et al. 1991) . Possession of extra wild-type copies of APP, such as found in Down Syndrome (DS) or in rare individuals without DS, is also linked to early-onset AD (Prasher et al. 1998; Cabrejo et al. 2006) . Additionally, a distinct variant of APP appears protective against AD (Jonsson et al. 2012) . The strongest genetic risk factor for the more common late-onset AD is the ε4 allele of apolipoprotein E (APOE4) (Corder et al. 1993; Liu et al. 2013) . Over 65-80% of AD patients carry an APOE4 allele Farrer et al. 1997) . The life-time risk for AD in people homozygous for APOE4 is extremely high (91%) relative to those with the more common APOE3 allele (20%) (Corder et al. 1993) . APOE4 is linked to more pronounced neurodegeneration (Holtzman et al. 2012) ; consequently, each copy of APOE4 decreases the predicted age of death relative to the more common APOE3 variant (Liu et al. 2013) . Even for early-onset AD, the APOE4 allele is associated earlier onset and more severe disease, including elevating levels of the amyloid-β1-40 peptide in the case of Down syndrome (Patel et al. 2011; Head et al. 2011) . This suggests that APP and APOE4 may contribute an additive or synergistic risk for AD onset and progression.
Despite the substantial influence of APOE4 on the progression of AD, how APOE4 modulates the molecular mechanisms underlying neurodegeneration remains elusive. Study of genetically modified mice has contributed to our understanding of the susceptibility to AD and other neurodegenerative diseases conferred by mutations or variants in APP, APOE, and related genes (Di Battista et al. 2016) . However, progress towards understanding the mechanistic underpinnings of some AD-related pathologies, particularly neurodegeneration, has been slower (reviewed in LaFerla and Green, 2012) . Many mouse models of AD do not show the extensive neuron loss that is present in the human condition. Moreover, it is more expensive and time-consuming to study age-related diseases in mice.
To surmount some of these limitations, we explored whether APOE could be studied in the context of APP-related neurodegeneration with the genetically tractable model nematode, Caenorhabditis elegans (Yi et al. 2017) . This minimal in vivo animal model offers several advantages for basic and applied research for AD. First, worms mature rapidly to adulthood reaching "middle-age" of adulthood only 3 days later as reproduction declines. Despite this compressed life span, C. elegans shares many of the genetic, cellular, and molecular processes of aging with humans and mice (Arey and Murphy 2016) . Thus, age-dependent processes can be studied within the span of one week with C. elegans. Second, forward and reverse genetics as well as transgenesis studies are extremely rapid with C. elegans. Third, every cell in the tiny (1 mm) worm is identified, including its 302 neurons, which can be examined individually using fluorescent reporters in the living, transparent worm. The function and health of even single identified neurons can be further probed by quantifying simple behaviors such as egg laying and locomotion. Fourth, several models of neurodegeneration related to AD have been generated using C. elegans (Griffin et al. 2017) . We recently described a transgenic worm strain that expresses a single copy of human APP and displays degeneration of a subset of cholinergic neurons in middle-age adulthood (Yi et al. 2017; Mondal et al. 2018) . Using this APP-expressing strain, we discovered small molecules that prevent degeneration of neurons in worm via a conserved signaling pathway and boost cognition in two mouse models of AD (Yi et al. 2017) .
Thus, although the simple worm cannot be used to study the important decline in cognition and memory as in mouse models, it can be used to directly study degeneration of identified neurons and to indirectly predict effective pharmacological approaches in rodent models of AD.
In this study, we tested how expressing variants of human APOE altered health and function of neurons in our worm model of APP-related neurodegeneration. We observed several key characteristics associated with AD. First, APOE4 caused a higher level of neurodegeneration than APOE3; and, APOE4 but not APOE3 acted in concert with APP to further increase neurodegeneration. This retains the isoform-specific effect of APOE that is welldocumented in human (Corder et al. 1993) . Second, APOE4 accelerated neurodegeneration in C. elegans, lowering the age of onset from late to early adulthood. This mirrors the expedited onset of degeneration in humans who carry APOE4 (Holtzman et al. 2012) . Lastly, despite deliberate expression of APP and APOE4 throughout the nervous system, the pattern of neurodegeneration in the worm model was restricted. This result mimics the fact that earlier and more extensive degeneration is found in specific brain regions, i.e. the hippocampus and the entorhinal cortex of AD patients despite the near-ubiquitous expression of APP and APOE in the human brain (Holtzman et al. 2012) . Because APOE variant expression influences C. elegans neurodegeneration in a manner similar to several key aspects found in human AD, our worm model may facilitate both the discovery of molecular pathways involved in the development of AD as well as novel drug discovery for the treatment of AD.
Materials and Methods

Plasmid and transgenic animals
The plasmid constructs for human APP or APOE transgenes under a pan-neuronal promoter (prab-3::APP::mCherry::UNC-54 UTR; prab-3::APOE4::UNC54 UTR; prab-3::APOE3::UNC54 UTR) were generated using Multi-site gateway technology (Invitrogen, Carlsbad, CA). Middle entry clones were made using the MultiSite Gateway Three-Fragment Vector Construction Kit (Invitrogen). cDNA for human APP695 or APOE variants (APOE3, APOE4) was amplified using the High Fidelity Phusion Polymerase (NEB) and recombined into pDONR221 using the BP clonase (Invitrogen). To generate the expression clones, theses middle entry clones were previously fused into pCFJ150 along with the 5' rab-3 promoter and 3' unc-54 UTR entry clones (Yi et al. 2014) using the LR clonase II (Invitrogen). Resulting plasmids were verified by sequencing. The construct for the GFP marker for HSN neurons was made by a PCR fusion of a ~2 kb region upstream of tph-1 amplified from genomic DNA and GFP::unc-54 UTR amplified from pPD95.75. The construct for the GFP marker for VA and VB neurons was made by a PCR fusion of a ~1.8 kb region upstream of del-1 amplified from genomic DNA and GFP::unc-54 UTR amplified from pPD95.75. The constructs for expressing APOE4 in the intestine and coelomocytes were made via NEBuilder® HiFi DNA Assembly. The promoter of fat-7 (~1.2 kb upstream of the gene) was amplified from genomic DNA while the promoter of unc-122 (~300 bp) was amplified from pCFJ68.
A single copy of human APP under a rab-3 promoter was inserted into the chromosome II of C. elegans via MosSCI transformation (Frøkjaer-Jensen et al. 2008) . The EG4322 strain was selected for the insertion of the construct at ttTi5605 II. Insertion of APP was confirmed in this APP strain by PCR and sequencing of the modified region on the chromosome.
Extrachromosomal array strains in this study were made by injecting expression plasmids and co-injection markers (1.2 ng/μl for pCFJ90, pmyo-2:mCherry, and 30 ng/μl for pCFJ68, punc-122::GFP, ptph-1::GFP) described by (Mello et al. 1991) . The extrachromosomal array for ptph-1::GFP was subsequently integrated using standard UV-integration techniques and outcrossed 6 times; this strain served as the wild-type (WT) background for all other strains.
We made three attempts to integrate the extrachromosomal array expressing APOE4 using traditional UV-integration techniques. However, the attempts were unsuccessful, at least in part due to a low survival rate after UV exposure. Instead, the array [prab-3::APOE4::UNC54 UTR; pmyo-2:mCherry] was integrated using CRISPR-cas9-based methods modified from Yoshina, Sawako et al. (2016) . Briefly, two plasmids containing the cas9 gene (pDD162) and a guide RNA targeting either the genomic region of integration (LG X:22.84, a location previously used for MosSCI insertions (Frøkjaer-Jensen et al. 2008) ) or a region on the extrachromosomal array (β-lactamase gene), and a co-injection marker (pCFJ104, pmyo-3:mCherry) were injected into worms carrying the APOE4 array. The sequences for guide RNAs used in the integration are as follow, 5'TTAATAGACTGGATGGAGG3' (β-lactamase gene), 5'ATGTGTCATAAGTCAACAAC3' and 5'TTATGTAGTCTCTTTCAGTG3' (X:22.84). The guide RNAs were made according to Ward (2015) . After non-homologous repair integrated the linearized array into the chromosome, we chose a strain with a similar intensity of red pharynx as that seen prior to integration.
The integrated APOE4 line was used to make the APOE4 (JPS844) and APOE4+APP (JPS845) strains. Subsequently, JPS845 was crossed with MT3002 (ced-3(n1286) IV) to obtain an APOE4+APP strain with a ced-3 null background. The genotypes for all the strains used in this study are listed in Table S1 .
Bag of worms assay
Worms were maintained at 20° C as previously described by Brenner (1974) . A total of 50 worms were synchronized by picking L4-stage larvae onto NGM agar plates seeded with OP50 bacteria. Worms were carefully examined every day for three days (Day 1-3 of adulthood) for the bag-of-worms phenotype indicated by the presence of hatched larvae within their body.
Groups of healthy worms with no hatched larvae were transferred to freshly seeded plate each day. The reported percentage bag-of-worms represents the number of bag-of-worms observed over the period of observation (2 or 3 days) relative to the total number of assayed worms. The assay was repeated 3-4 times for each genotype and expressed as % bag-of-worms ± 95% confidence interval. Group comparisons were made with planned χ 2 -tests.
Scoring of neurodegeneration
Worms maintained at 20° C and synchronized by picking L4-stage larvae onto NGM plates seeded with OP50 bacteria and containing 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR, 200 µL of a 16.8-mM stock per 12-cm plate) to sterilize adults and prevent non-specific consequences of larvae hatching inside adults. Prior to scoring neuron health, worms were cleaned by transferring them to an unseeded plate until they left no residual tracks of bacteria, a process that took <10 mins. Worms were mounted on 2% agarose pads, immobilized with 30-mM sodium azide and imaged at 40X. For strains with no or extrachromosomal expression of APOE (Figure 1) , HSN neurons were considered healthy when both HSNL and HSNR were present and the processes were intact. HSNs were considered degenerated when one or both neurons was absent and/or displayed significant morphological abnormalities (e.g, blebbing, beading and absence of processes). Examples of degenerated HSN neurons following these criteria can be found in Figure S1 . We observed dimmer GFP expression in the HSNs of integrated APOE4 strains ( Figure 2 ) making it more difficult to visualize the HSN processes.
Thus, HSN health in these strains (JPS844 vs. JPS845) was based exclusively on the presence or absence of the HSN cell-bodies. That is, HSNs were considered to be degenerated when one or both HSN neurons were absent. Neuron health was scored with the observer blind to genotype. An average of 50 worms were scored per strain for each trial. Scoring was repeated 3-4 times for each genotype and expressed as % HSN degeneration ± 95% confidence interval.
Group comparisons were made with planned χ 2 -tests.
Locomotion assay
Worms were cleaned of bacteria as described above. Approximately 15 worms were moved into a 5/8-inch-diameter copper ring sealed on a standard unseeded NGM agar plate.
Movement was recorded for 2 min at 2 frames/sec with a FLEA digital camera (Point Gray, Richmond, BC, Canada). The distance that the worms crawled during 1 min was measured using a semiautomated procedure in ImagePro Plus (Media Cybernetics, Rockville, MD) to objectively calculate overall speed of individual worms. Speed for each group is expressed group mean ± SEM. Group comparisons were made with planned Student's t-tests.
Results
APP expression exacerbates APOE4-induced neurodegeneration in HSN neurons
We previously developed a C. elegans model of neurodegeneration that expressed a single-copy of human APP and showed age-related degeneration of a subset of cholinergic neurons (Yi et al. 2017; Mondal et al. 2018) . Specifically, six VC-class neurons located in the middle of the ventral nerve cord begin to die as the worm advances past Day 3 of adulthood. To investigate whether variants in APOE modify neurodegeneration phenotypes in our APP worm model, we generated strains that expressed human APOE4 or APOE3, with or without human APP. Both APP and APOE transgenes were expressed throughout the nervous system using the conventional pan-neuronal rab-3 promoter to mimic widespread brain expression in mammals (Stefanakis et al. 2015) . APP was integrated while initially APOE transgenes were expressed with extrachromosomal arrays. Comparisons were made between these strains and a wild-type background (WT).
Despite the degeneration of VC neurons in our APP-expressing strain, the expression of human APP alone did not confer any obvious behavioral defects (Mondal et al. 2018) . To test if APOE variants caused gross phenotypic differences that may be indicative of neuronal degeneration or dysfunction beyond that observed in our strain only expressing APP, we evaluated the behavior of APOE3-or APOE4-expressing strains. We observed an increase in a behavioral phenotype called 'bag-of-worms' (BW) in strains expressing APOE4 but not APOE3 (Fig. 1A) . C. elegans normally lays eggs that hatch outside the parent. However, eggs are retained inside the parent under stressful conditions of starvation, or when the neurons that mediate egg-laying become dysfunctional or die (Schafer, 2005) . If eggs are retained too long in the worm, they hatch and fill the parent with writhing larvae (Angelo and Van Glist 2009 ). This BW phenotype can be unambiguously detected at low power via a stereomicroscope and has proven convenient to study many biological processes (e.g. Trent et al. 1983; Condradt and Horvitz, 1998) .
When we quantified the amount of BW by observing worms for 3 days throughout the C. elegans reproductive period, we found that WT worms displayed a low level of BW as expected. The incidence of BW was not raised in strains expressing APP or APOE3. However, APOE4-expressing strains had a significantly higher percentage of BW than WT, APP-, and APOE3-expressing strains (Fig. 1A) . Worms expressing both APOE4 and APP displayed an even higher incidence of BW than worms expressing either APOE4 or APP alone (Fig. 1A) . In contrast, the percentage BW in strains expressing both APOE3 and APP remained low and was not significantly higher than that found in strains expressing either gene individually (Fig. 1A) .
The lack of affect of APOE3 could not be easily explained by a lower number of APOE3 transgene copies on the extrachromosome versus APOE4 copies because an independent strain made with a higher (2x) transformative dose (exAPOE3h) showed a low level of BW indistinguishable from the APP strain (Fig. 1A) .
Because the APOE4-expressing strains displayed the BW phenotype even when well fed, this suggested that one or more of the egg-laying neurons were dysfunctional or dying.
Egg-laying is controlled primarily by the left-right pair of HSN neurons and to a much lesser extent by VC4 and VC5 neurons (Schafer, 2005) . The HSN and VC4 and VC5 neurons connect to each by reciprocal synapses (Altun and Hall, 2018) . We checked the health of these neurons by directly visualizing them with a fluorescent reporter through the worm's transparent body (see methods). We considered HSN neurons "degenerated" when one or both neurons was absent and/or displayed significant morphological abnormalities (e.g, blebbing, beading and absence of processes) (see Fig. 1B and S1 ). Additionally, we saw clear degeneration of HSN neurons in APOE4-expressing strains with or without co-expression of APP. As for BW behavior, the incidence of HSN neuron degeneration was significantly higher in worms expressing both APP and APOE4 than those expressing either APP or APOE4 alone ( Fig 1C) . Intriguingly, although expression of APOE4 increased degeneration of HSN neurons, the expression of APOE3 with or without APP co-expression did not increase HSN degeneration relative to WT (Fig. 1C) . Even when the APOE3 transgene was transformed at double the concentration of the APOE4 transgene and combined with APP expression, the resulting strains exhibited a percentage BW and HSN neurodegeneration that was not significantly higher than WT (Fig. 1A,C) .
Taken together, these results suggest that the pan-neuronal expression of APOE4 with APP expands degeneration from the VC class neurons to the presynaptic HSN neuron pair.
Further, co-expression of APOE4 with APP extends the level of HSN neurodegeneration beyond that observed when either gene is expressed singly.
Neuronal APOE4 causes selective neurodegeneration Thus far, we used extrachromosomal arrays to express the APOE transgenes. Although extrachromosomal arrays represent a convenient approach to express transgenes, these arrays are not perfectly carried through cell division which gives rise to mosaic individuals (Leung-Hagesteijn et al. 1992) . Moreover, the expression of extrachromosomal transgenes are sometimes suppressed (Hsieh and Fire, 2000) . To control for these potential caveats, we sought to integrate the APOE4 transgene array into the worm's X chromosome and re-evaluate BW phenotype and HSN degeneration. In this way, each cell in the worm would be expected to faithfully express the APOE4 transgene. We again assayed BW and HSN neurodegeneration, breaking down the incidence as a function of age. The integrated APOE4 and APOE4+APP strains retained a comparable percentage of BW as observed in the extrachromosomal array strains by Day 3 of adulthood ( Fig. 1A vs. Fig. 2A ). Interestingly, not only was the total incidence of BW higher in the APOE4+APP strain by Day 3 of adulthood, but the total incidence of BW was already substantially raised by Day 2 of adulthood relative to that seen in the APOE4 strain ( Fig. 2A) . Though both of the APP and APOE4+APP strains showed age-dependent degeneration in HSN neurons, the degree of degeneration was worse in the APOE4+APP strain (Fig. 2C) . This is consistent with our findings for the extrachromosomal strains.
Consistent with previous findings, we observed signs of APP-related degeneration in the VC4 and VC5 neurons. However, APOE4 expression greatly exacerbated HSN degeneration but not VC4 and VC5 degeneration when APOE4 was co-expressed with APP. Using our integrated strains, we found that 27% of APOE4+APP worms were missing both HSN neurons on Day 3 of adulthood (vs. 6% in WT, N>300). Less than 1% of either APOE4+APP or WT worms were completely missing VC4 or VC5.
Under the conventional pan-neuronal rab-3 promoter APOE4 and APP were expressed in almost all neurons; but, aside from the BW phenotype no other abnormal behaviors were grossly apparent in the APOE4+APP strain. This suggests that many neurons in this strain remain intact. For instance, the APOE4+APP strain did not seem to have defects in locomotion compared to WT worms as measured by their speed (Fig. 3B ). The crawling speed was indistinguishable on both Day 1 and Day 3 of adulthood between WT and APOE4+APP worms ( Fig. 3B) . Consistent with this behavioral observation, when we looked at VA and VB cholinergic motor neurons, which control locomotion, and we saw no qualitatively discernable differences in morphology and number of VA and VB neurons between WT and APOE4+APP worms (Fig.   3A ).
Next, we asked whether APOE4 induces neurodegeneration when expressed outside the nervous system on a pan-neuronal APP background. Using extrachromosomal arrays, we expressed APOE4 in organs involved in metabolic and excretory functions, the coelomocytes and intestine, using the unc-122 and fat-7 promoter, respectively. Unlike with pan-neuronally expressed APOE4, the incidence of BW was as low for strains expressing APOE4 in either coelomocytes or intestine as in the background APP strains (Fig. 4A) . This low percentage of BW for strains with APOE4 expressed in coelomocytes or intestine corresponded with low levels of HSN degeneration in these strains (Fig. 4B,C) .
To better understand the mechanism of degeneration, we investigated whether HSN neurons degenerate in manner dependent on apoptosis. We crossed the ced-3(n1286) null mutation into the integrated APOE4+APP strain. CED-3 is an executioner caspase that is part of the core apoptotic machinery in worm (Yuan et al. 1993) . We found that the incidence of both BW and HSN neurodegeneration did not decrease in APOE4+APP strains with or without a mutation in this key apoptotic caspase (Fig. 5A-C) . Thus, pan-neuronal co-expression of APOE4 and APP appears to cause HSN neurons to degenerate via a mechanism other than apoptosis.
Discussion
In this study, we present a novel Alzheimer's disease model in C. elegans. Although worms cannot model all aspects of human AD, our model mirrors three important characteristics: isoform-specific degeneration, age-dependent degeneration, and cell-specific degeneration. In humans, the allele ε4 of APOE (APOE4) increases the risk as well as the mean age of clinical onset of AD in a copy-dependent manner (Corder et al. 1993) . The more common APOE variant in humans, APOE3, does not confer this relative risk. Our data show that APOE4, but not APOE3, causes degeneration in a subset of neurons in C. elegans. APP co-expression enhances this APOE4-related degeneration of the HSN neurons in C. elegans. By contrast, the HSN neurons do not appear to degenerate when APP is expressed alone. Similarly, in APOEtarget replacement (TR) mouse models engineered on an amyloid-β transgenic background, pathological phenotypes, including amyloid-β deposition, are observed at a higher level in APOE4-TR mice than APOE3-TR mice (Bales et al. 2009; Fryer et al. 2005) . However, studies that show a direct mechanistic link between APP and APOE4 for neurodegeneration are still lacking.
In our worm APOE4-expressing strains, HSN neurons display neurodegeneration by becoming dim, shrinking, forming blebs, and disappearing in many animals. We also found that the long axonal processes of HSN neurons, which extend anteriorly to synapse onto neurons in the nerve ring, undergo beading. This is reminiscent of how neuronal processes degenerate after laser axonomy (Yanik et al. 2006) . In mice, targeted replacement of ApoE with human APOE4 causes dendrites of neurons in the amygdala to shrink compared to the dendrites of APOE3 TR mice (Klein et al. 2010) . These morphological changes in the processes of dying neurons suggest that there might be conserved pathways for degeneration at this cellular level.
One of the prominent characteristics of AD is age-dependent neurodegeneration. Coexpression of APP with APOE4 throughout the nervous system in C. elegans enhances the incidence of APOE4-related neurodegeneration. Interestingly, the cumulative effect of APP and APOE4 expression manifests more strongly in "middle age" adulthood, suggesting that the additive insult may arise from an age-related process. In patients with Down syndrome who carry an extra copy of APP, APOE4 appears to expedite the onset of their early-onset AD and accelerate the progression of neurodegeneration (Patel et al. 2011; Head et al. 2011) .
In humans, neurodegeneration occurs more extensively in certain regions of the brain, such as hippocampus and entorhinal cortex (Saxena and Caroni 2011; Colin et al. 2015) . This aspect is one of the more curious observations in AD patients because APP and APOE4 are both expressed throughout the brain (Huang and Mucke 2012) . Similarly, our results show that the VA and VB cholinergic neurons did not degenerate despite the pan-neuronal expression of APP and APOE4 transgenes and proximity to the vulnerable VC neurons. The restricted pattern of APOE4-dependent degeneration in worm suggests that there are cellular and/or molecular characteristics that confer resistance or vulnerability to APOE4 expression that may make them resistant (e.g., VA and VB) or vulnerable (e.g., HSNs).
Although APOE4 is expressed in both the liver and the nervous system in human (Holtzman et al. 2012; Liu et al. 2013; Mahley et al. 2006) , it is unclear whether hepatic, neuronal, or both types of APOE4 contribute to neurodegeneration. We were interested in exploring whether APOE4-induced degeneration is tissue-specific. Recent studies have demonstrated clear examples of cell non-autonomous signaling between neuronal and nonneuronal tissue in C. elegans (van Oosten-Hawle et al. 2013; Taylor and Dillin 2013; Melentijevic et al. 2017) . For instance, unfolded protein responses, which may underlie neurodegeneration, are interdependently co-activated between the nervous systems and the intestine (van Oosten-Hawle et al. 2013; Taylor and Dillin 2013) . Additionally, when under stress worm neurons jettison particles extracellularly to become absorbed by coelomocytes (Melentijevic et al. 2017) . Taken together, these studies suggest that APOE4 could very well influence neurodegeneration when expressed outside of the neurons. However, after probing expression in both intestine and coelmocytes, our results indicate that APOE4 mainly induces degeneration when expressed in the nervous system of C. elegans. These results are consistent with other work showing the sufficiency of neuronal APOE4 expression in causing exacerbated cellular or behavioral deficits. For example, in mice neuronal APP can cause degeneration and memory deficits when co-expressed with APOE4 (Bien-Ly et al. 2011; Harris et al. 2013) .
To begin to understand the basis for neurodegeneration in our model, we asked whether degeneration of HSN neurons required apoptosis. CED-3 is the primary executioner caspase that initiates the cascade of apoptosis (Yuan et al. 1993) . When a ced-3 null mutation was crossed into the APOE4+APP strain, we saw no reduction of the bag-of-worms phenotype or HSN neurodegeneration. This indicates that apoptosis is likely not involved in APOE4dependent degeneration in C. elegans. Other C. elegans neurodegenerative models similarly show that ced-3 and other broad apoptotic mechanisms do not play a role in degeneration (Liachko et al. 2010) . Despite extensive research into its developmental role, the role of apoptosis in adult C. elegans is inconclusive at best. Further studies are required to elucidate the mechanism of neurodegeneration in our APOE4 model in C. elegans. Our model is well positioned to be used to explore how patterned neurodegeneration may arise in AD and other neurodegenerative diseases. strain was compared with the background APP strain using χ 2 tests. Alpha was set at 0.015 to correct for multiple comparisons (*p < 0.015). 
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